Advertisement

FDG PET/CT in Autoimmune Diseases

  • Alok Pawaskar
  • Sandip Basu
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Systemic autoimmune diseases are a heterogeneous group of disorders in which “self-tolerance” has been overcome by genetic and environmental factors and an immune response has been mounted against the body’s own organs, tissues, and cells. Diagnosis and treatment monitoring of these diseases is primarily done by clinical evaluation, inflammatory markers and biopsy wherever feasible. Role of anatomical imaging is limited to demonstrating tissue or organ destruction caused by the autoimmune processes. Functional imaging, on the other hand, can show the actual process of inflammation caused by activated immune cells in the target organ. Traditionally 99mTc-colloid, radiolabelled immunoglobulins, bone scan, Gallium-67 scan have been used for this purpose. FDG PET/CT has been extensively used as research tool in autoimmune disorders (AID) and have demonstrated promising results in a variety of AID.

References

  1. 1.
    Ramos-Casals M, Brito-Zeron P, Lopez-Soto A, Font J. Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia. Autoimmun Rev. 2004;3:376–82.CrossRefPubMedGoogle Scholar
  2. 2.
    Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev. 2010;9:195–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Sela O, Shoenfeld Y. Cancer in autoimmune diseases. Semin Arthritis Rheum. 1988;18:77–87.CrossRefPubMedGoogle Scholar
  4. 4.
    Bleeker-Rovers CP, Bredie SJ, van der Meer JW, Corstens FH, Oyen WJ. F-18-fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med. 2003;61(10):323–9.PubMedGoogle Scholar
  5. 5.
    Zerizer I, Tan K, Khan S, Barwick T, Marzola MC, Rubello D, et al. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol. 2010;73(3):504–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med. 2009;39(2):124–45.CrossRefPubMedGoogle Scholar
  7. 7.
    Walter MA, Melzer RA, Schindler C, Muller-Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005;32(6):674–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol. 2011;30(10):1265–75.CrossRefPubMedGoogle Scholar
  9. 9.
    Marienhagen J, Geissler A, Lang B. High resolution single photon emission computed tomography of the brain in Wegener’s granulomatosis. J Rheumatol. 1996;23:1828–30.PubMedGoogle Scholar
  10. 10.
    Wildhagen K, Stoppe G, Meyer GJ, et al. [Imaging diagnosis of central nervous system involvement in panarteritisnodosa]. Z Rheumatol. 1989;48:323–5.Google Scholar
  11. 11.
    van Dam AP. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int. 1991;11:1–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Bicik I, Bauerfeind P, Breitbach T, von Schulthess GK, Fried M. Inflammatory bowel disease activity measured by positron-emission tomography. Lancet. 1997;350(9073):262.CrossRefPubMedGoogle Scholar
  13. 13.
    Neurath MF, Vehling D, Schunk K, Holtmann M, Brockmann H, Helisch A, et al. Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol. 2002;97(8):1978–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Treglia G, Quartuccio N, Sadeghi R, Farchione A, Caldarella C, Bertagna F, et al. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis. J Crohns Colitis. 2013;7(5):345–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Lenze F, Wessling J, Bremer J, Ullerich H, Spieker T, Weckesser M, et al. Detection and differentiation of inflammatory versus fibromatous Crohn’s disease strictures: prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflamm Bowel Dis. 2012;18(12):2252–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, et al. Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med. 2009;50(11):1751–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M. PET/CT in the evaluation of inflammatory bowel disease: studies in patients before and after treatment. Mol Imaging Biol. 2010;12(1):85–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Malham MHS, Nielse RG, Husby S, Høilund-Carlsen PF. PET/CT in the diagnosis of inflammatory bowel disease in pediatric patients: a review. Am J Nucl Med Mol Imaging. 2014;4(3):225–30.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Das CJ, Makharia GK, Kumar R, Kumar R, Tiwari RP, Sharma R, et al. PET/CT colonography: a novel non-invasive technique for assessment of extent and activity of ulcerative colitis. Eur J Nucl Med Mol Imaging. 2010;37(4):714–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Yun M, Kim W, Adam LE, Alnafisi N, Herman C, Alavi A. F-18 FDG uptake in a patient with psoriatic arthritis: imaging correlation with patient symptoms. Clin Nucl Med. 2001;26(8):692–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Takata T, Taniguchi Y, Ohnishi T, Kohsaki S, Nogami M, Nakajima H, et al. (18)FDG PET/CT is a powerful tool for detecting subclinical arthritis in patients with psoriatic arthritis and/or psoriasis vulgaris. J Dermatol Sci. 2011;64(2):144–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Carey K, Saboury B, Basu S, Brothers A, Ogdie A, Werner T, et al. Evolving role of FDG PET imaging in assessing joint disorders: a systematic review. Eur J Nucl Med Mol Imaging. 2011;38(10):1939–55.CrossRefPubMedGoogle Scholar
  23. 23.
    Beckers C, Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med. 2004;45(6):956–64.PubMedGoogle Scholar
  24. 24.
    Roivainen A, Hautaniemi S, Mottonen T, Nuutila P, Oikonen V, Parkkola R, et al. Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging. 2013;40(3):403–10.CrossRefPubMedGoogle Scholar
  25. 25.
    Okamura K, Yonemoto Y, Arisaka Y, Takeuchi K, Kobayashi T, Oriuchi N, et al. The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology. 2012;51(8):1484–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Kumar NS, Shejul Y, Asopa R, Basu S. Quantitative metabolic volumetric product on 18Fluorine-2fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in assessing treatment response to disease-modifying antirheumatic drugs in rheumatoid arthritis: multiparametric analysis integrating American College of Rheumatology/European League against rheumatism criteria. World J Nucl Med. 2017;16(4):293–302.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Vijayant V, Sarma M, Aurangabadkar H, Bichile L, Basu S. Potential of (18)F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies. World J Radiol. 2012;4(12):462–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rose S, Sheth NH, Baker JF, Ogdie A, Raper A, Saboury B, et al. A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study. Am J Cardiovasc Dis. 2013;3(4):273–8.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Basu S, Shejul Y. Regional lymph node hypermetabolism corresponding to the involved joints on FDG-PET in newly diagnosed patients of rheumatoid arthritis: observation and illustration in symmetrical and asymmetric joint involvement. Rheumatol Int. 2014;34(3):413–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Sarma M, Vijayant V, Basu S. (18)F-FDG-PET assessment of early treatment response of articular and extra-articular foci in newly diagnosed rheumatoid arthritis. Hell J Nucl Med. 2012;15(1):70–1.PubMedGoogle Scholar
  32. 32.
    Faria D, Copray S, Buchpiguel C, Dierckx R, de Vries E. PET imaging in multiple sclerosis. J Neuroimm Pharm. 2014;9(4):468–82.CrossRefGoogle Scholar
  33. 33.
    Sørensen P, Jønsson A, Mathiesen H, Blinkenberg M, Andresen J, Hanson L, Ravnborg M. The relationship between MRI and PET changes and cognitive disturbances in MS. J Neurol Sci. 2006;245(1-2):99–102.CrossRefPubMedGoogle Scholar
  34. 34.
    Bakshi R, Miletich R, Kinkel P, Emmet M, Kinkel W. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging. 1998;8(4):228–34.CrossRefPubMedGoogle Scholar
  35. 35.
    Derache N, Marié R, Constans J, Defer G. Reduced thalamic and cerebellar rest metabolism in relapsing-remitting multiple sclerosis, a positron emission tomography study: correlations to lesion load. J Neurol Sci. 2006;245(1-2):103–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Mishina M, Senda M, Ohyama M, et al. Regional cerebral glucose metabolism associated with ataxic gait—an FDG-PET activation study in patients with olivopontocerebellar atrophy. Rinsho Shinkeigaku. 1995;35(11):1199–204.PubMedGoogle Scholar
  37. 37.
    Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, et al. Striatal 18F-dopa uptake and brain glucose metabolism by PET in patients with syndrome of progressive ataxia. J Neurol Sci. 1994;124(2):198–203.CrossRefPubMedGoogle Scholar
  38. 38.
    Fisher R, Patel N, Lai E, Schulz P. Two different 18F-FDG brain PET metabolic patterns in autoimmune limbic encephalitis. Clin Nucl Med. 2012;37:213–8.CrossRefGoogle Scholar
  39. 39.
    Rey C, Koric L, Guedj E, et al. Striatal hypermetabolism in limbic encephalitis. J Neurol. 2012;259:1106–10.CrossRefPubMedGoogle Scholar
  40. 40.
    Shih WJ, Ghesani N, Hongming Z, et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin’s lymphoma of the parotid gland in a patient with Sjogren’s syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med. 2002;27:142–3.CrossRefPubMedGoogle Scholar
  41. 41.
    Nakajo M, Jinnouchi S, Noguchi M, et al. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. Clin Nucl Med. 2007;32:282–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Lee TY, Kim M-H, Park DH, et al. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR. 2009;193:343–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen YK, Chen YL, Cheng RH, et al. The significance of FDG uptake in bilateral thyroid glands. Nucl Med Commun. 2007;28(2):117–22.CrossRefPubMedGoogle Scholar
  44. 44.
    Zhang J, Chen H, Ma Y, Xiao Y, Niu N, Lin W, Wang X, Liang Z, Zhang F, Li F, Zhang W, Zhu Z. Characterizing IgG4-related disease with 18F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging. 2014;41(8):1624–34.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Martinez-Pimienta G, Noriega-Álvarez E, Simó-Perdigó M. Study of systemic disease IgG4. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose -positron emission tomography/computed tomography for staging, selection of biopsy site, evaluation of treatment response and follow-up. Eur J Rheumatol. 2017;4(3):222–5.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Basu S, Utpat K, Joshi J. 18F-FDG PET/CT imaging features of IgG4-related pulmonary inflammatory pseudotumor at initial diagnosis and during early treatment monitoring. J Nucl Med Technol. 2016;44(3):207–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Alok Pawaskar
    • 2
    • 1
  • Sandip Basu
    • 2
    • 3
  1. 1.Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre AnnexeMumbaiIndia
  2. 2.HCG Manavata Cancer CentreNashikIndia
  3. 3.Homi Bhabha National InstituteMumbaiIndia

Personalised recommendations